PDX TM00089 is derived from a patient with a germline pathogenic v757fs*BRCA1 mutation (truncation) who had received prior cisplatin/taxol therapy for a fallopian tube carcinoma ([31]; Mouse Models of Human Cancer Database, Jackson Research Labs). The gene discussed is BRCA1; the disease is cancer.